-
1
-
-
33847348491
-
Systemic sclerosis: a prototypic multisystem fibrotic disorder
-
Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557-67.
-
(2007)
J Clin Invest
, vol.117
, pp. 557-567
-
-
Varga, J.1
Abraham, D.2
-
2
-
-
0038076254
-
National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study
-
Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol. 2003;30:958.
-
(2003)
J Rheumatol
, vol.30
, pp. 958
-
-
Thomas, E.1
Symmons, D.P.2
Brewster, D.H.3
Black, R.J.4
Macfarlane, G.J.5
-
3
-
-
77956631231
-
Evidence-based management of rapidly progressing systemic sclerosis
-
Khanna D, Denton CP. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol. 2010;24:387-400.
-
(2010)
Best Pract Res Clin Rheumatol
, vol.24
, pp. 387-400
-
-
Khanna, D.1
Denton, C.P.2
-
4
-
-
2142646426
-
TGF-beta signaling and the fibrotic response
-
Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J. 2004;18:816-27.
-
(2004)
FASEB J
, vol.18
, pp. 816-827
-
-
Leask, A.1
Abraham, D.J.2
-
5
-
-
65849108890
-
Role of PDGF in fibrotic diseases and systemic sclerosis
-
Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford). 2008;47:v2-4.
-
(2008)
Rheumatology (Oxford)
, vol.47
, pp. v2-v4
-
-
Trojanowska, M.1
-
6
-
-
36348968931
-
Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
-
Kantarjian HM, Giles F, Gattermann N, Bhalia K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540-6.
-
(2007)
Blood
, vol.110
, pp. 3540-3546
-
-
Kantarjian, H.M.1
Giles, F.2
Gattermann, N.3
Bhalia, K.4
Alimena, G.5
Palandri, F.6
-
7
-
-
46749154199
-
Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis
-
Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jüngel A, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008;22:2214-22.
-
(2008)
FASEB J
, vol.22
, pp. 2214-2222
-
-
Akhmetshina, A.1
Dees, C.2
Pileckyte, M.3
Maurer, B.4
Axmann, R.5
Jüngel, A.6
-
8
-
-
84887463104
-
Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors
-
Maurer B, Distler A, Dees C, Khan K, Denton CP, Abraham D, et al. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Ann Rheum Dis. 2013;72:2039-46.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 2039-2046
-
-
Maurer, B.1
Distler, A.2
Dees, C.3
Khan, K.4
Denton, C.P.5
Abraham, D.6
-
9
-
-
84855283317
-
Tyrosine kinase inhibitors in the treatment of systemic sclerosis: The difficulty in interpreting proof-of-concept studies
-
Gordon J, Spiera R. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: The difficulty in interpreting proof-of-concept studies. Int J Rheumatol. 2011;2011:842181.
-
(2011)
Int J Rheumatol
, vol.2011
, pp. 842181
-
-
Gordon, J.1
Spiera, R.2
-
10
-
-
79955860261
-
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial
-
Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011;70:1003-9.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1003-1009
-
-
Spiera, R.F.1
Gordon, J.K.2
Mersten, J.N.3
Magro, C.M.4
Mehta, M.5
Wildman, H.F.6
-
11
-
-
80155204477
-
A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease
-
Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011;63:3540-6.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 3540-3546
-
-
Khanna, D.1
Saggar, R.2
Mayes, M.D.3
Abtin, F.4
Clements, P.J.5
Maranian, P.6
-
12
-
-
80155206225
-
Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center
-
Pope J, McBain D, Petrlich L, Watson S, Vanderhoek L, de Leon F, et al. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum. 2011;63:3547-51.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 3547-3551
-
-
Pope, J.1
McBain, D.2
Petrlich, L.3
Watson, S.4
Vanderhoek, L.5
Leon, F.6
-
13
-
-
84868214290
-
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial
-
Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol. 2012;167:1138-44.
-
(2012)
Br J Dermatol
, vol.167
, pp. 1138-1144
-
-
Prey, S.1
Ezzedine, K.2
Doussau, A.3
Grandoulier, A.S.4
Barcat, D.5
Chatelus, E.6
-
14
-
-
85028112070
-
Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
-
Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, et al. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014;16:R144.
-
(2014)
Arthritis Res Ther
, vol.16
, pp. R144
-
-
Fraticelli, P.1
Gabrielli, B.2
Pomponio, G.3
Valentini, G.4
Bosello, S.5
Riboldi, P.6
-
15
-
-
75349094716
-
Extended kinase profile and properties of the protein kinase inhibitor Nilotinib
-
Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, et al. Extended kinase profile and properties of the protein kinase inhibitor Nilotinib. Biochim Biophys Acta. 2010;1804:445-53.
-
(2010)
Biochim Biophys Acta
, vol.1804
, pp. 445-453
-
-
Manley, P.W.1
Drueckes, P.2
Fendrich, G.3
Furet, P.4
Liebetanz, J.5
Martiny-Baron, G.6
-
16
-
-
0018887574
-
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis
-
(scleroderma)
-
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
-
(1980)
Arthritis Rheum
, vol.23
, pp. 581-590
-
-
-
17
-
-
0034937852
-
Criteria for the classification of early systemic sclerosis
-
LeRoy EC, Medsger Jr TA. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573-6.
-
(2001)
J Rheumatol
, vol.28
, pp. 1573-1576
-
-
LeRoy, E.C.1
Medsger, T.A.2
-
18
-
-
42649123535
-
National Cancer Institute
-
Common Terminology Criteria for Adverse Events (CTCAE). National Cancer Institute. 2010. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf . Accessed 5 Aug 2015.
-
(2010)
-
-
-
19
-
-
85081879509
-
Highlights of Prescribing Information
-
Highlights of Prescribing Information. Novartis Pharmaceuticals. 2015. http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf . Accessed 5 Aug 2015.
-
(2015)
Novartis Pharmaceuticals
-
-
-
20
-
-
84880326024
-
Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis
-
Hinchcliff M, Huang CC, Wood TA, Matthew Mahoney J, Martyanov V, Bhattacharyya S, et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol. 2013;133:1979-89.
-
(2013)
J Invest Dermatol
, vol.133
, pp. 1979-1989
-
-
Hinchcliff, M.1
Huang, C.C.2
Wood, T.A.3
Matthew Mahoney, J.4
Martyanov, V.5
Bhattacharyya, S.6
-
21
-
-
33646361583
-
GenePattern 2.0
-
Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet. 2006;38:500-1.
-
(2006)
Nat Genet
, vol.38
, pp. 500-501
-
-
Reich, M.1
Liefeld, T.2
Gould, J.3
Lerner, J.4
Tamayo, P.5
Mesirov, J.P.6
-
23
-
-
33747842275
-
Comparative gene marker selection suite
-
Gould J, Getz G, Monti S, Reich M, Mesirov JP. Comparative gene marker selection suite. Bioinformatics. 2006;22:1924-5.
-
(2006)
Bioinformatics
, vol.22
, pp. 1924-1925
-
-
Gould, J.1
Getz, G.2
Monti, S.3
Reich, M.4
Mesirov, J.P.5
-
24
-
-
9444225935
-
Java Treeview-extensible visualization of microarray data
-
Saldanha AJ. Java Treeview-extensible visualization of microarray data. Bioinformatics. 2004;20:3246-8.
-
(2004)
Bioinformatics
, vol.20
, pp. 3246-3248
-
-
Saldanha, A.J.1
-
25
-
-
27344435774
-
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles
-
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545-50. Epub 2005 Sep 30.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 15545-15550
-
-
Subramanian, A.1
Tamayo, P.2
Mootha, V.K.3
Mukherjee, S.4
Ebert, B.L.5
Gillette, M.A.6
-
26
-
-
0038054341
-
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
-
Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267-73.
-
(2003)
Nat Genet
, vol.34
, pp. 267-273
-
-
Mootha, V.K.1
Lindgren, C.M.2
Eriksson, K.F.3
Subramanian, A.4
Sihag, S.5
Lehar, J.6
-
27
-
-
70449091786
-
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
-
Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108-12.
-
(2009)
Nature
, vol.462
, pp. 108-112
-
-
Barbie, D.A.1
Tamayo, P.2
Boehm, J.S.3
Kim, S.Y.4
Moody, S.E.5
Dunn, I.F.6
-
28
-
-
49949114547
-
Molecular subsets in the gene expression signatures of scleroderma skin
-
Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One. 2008;3, e2696.
-
(2008)
PLoS One
, vol.3
-
-
Milano, A.1
Pendergrass, S.A.2
Sargent, J.L.3
George, L.K.4
McCalmont, T.H.5
Connolly, M.K.6
-
29
-
-
84859760888
-
Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies
-
Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, Whitfield ML. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol. 2012;132:1363-73.
-
(2012)
J Invest Dermatol
, vol.132
, pp. 1363-1373
-
-
Pendergrass, S.A.1
Lemaire, R.2
Francis, I.P.3
Mahoney, J.M.4
Lafyatis, R.5
Whitfield, M.L.6
-
30
-
-
77953691179
-
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
-
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-9.
-
(2010)
N Engl J Med
, vol.362
, pp. 2251-2259
-
-
Saglio, G.1
Kim, D.W.2
Issaragrisil, S.3
Coutre, P.4
Etienne, G.5
Lobo, C.6
-
31
-
-
79251546724
-
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
-
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141-5.
-
(2011)
Blood
, vol.117
, pp. 1141-1145
-
-
Kantarjian, H.M.1
Giles, F.J.2
Bhalla, K.N.3
Pinilla-Ibarz, J.4
Larson, R.A.5
Gattermann, N.6
-
32
-
-
84902993757
-
Cardiac arrhythmias and conduction defects in systemic sclerosis
-
Vacca A, Meune C, Gordon J, Chung L, Proudman S, Assassi S, et al. Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatology (Oxford). 2014;53:1172-7.
-
(2014)
Rheumatology (Oxford)
, vol.53
, pp. 1172-1177
-
-
Vacca, A.1
Meune, C.2
Gordon, J.3
Chung, L.4
Proudman, S.5
Assassi, S.6
-
33
-
-
79959361633
-
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML
-
Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533-9. doi: 10.1002/ajh.22037 . Epub 2011 Apr 27.
-
(2011)
Am J Hematol
, vol.86
, pp. 533-539
-
-
Aichberger, K.J.1
Herndlhofer, S.2
Schernthaner, G.H.3
Schillinger, M.4
Mitterbauer-Hohendanner, G.5
Sillaber, C.6
-
35
-
-
33750367940
-
Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study
-
Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study. Ann Rheum Dis. 2006;65:1325-9.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 1325-1329
-
-
Khanna, D.1
Furst, D.E.2
Hays, R.D.3
Park, G.S.4
Wong, W.K.5
Seibold, J.R.6
-
36
-
-
0038799774
-
Natural History of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being
-
Medsger T. Natural History of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin N Am. 2003;255-273.
-
(2003)
Rheum Dis Clin N Am.
, pp. 255-273
-
-
Medsger, T.1
-
37
-
-
68049111578
-
Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials
-
Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum. 2009;60:2490-8.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 2490-2498
-
-
Amjadi, S.1
Maranian, P.2
Furst, D.E.3
Clements, P.J.4
Wong, W.K.5
Postlethwaite, A.E.6
-
38
-
-
84901810710
-
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
-
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071.
-
(2014)
N Engl J Med
, vol.370
, pp. 2071
-
-
Richeldi, L.1
Bois, R.M.2
Raghu, G.3
Azuma, A.4
Brown, K.K.5
Costabel, U.6
-
39
-
-
84863469731
-
Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis
-
Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2012;64:3420-9.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 3420-3429
-
-
Merkel, P.A.1
Silliman, N.P.2
Clements, P.J.3
Denton, C.P.4
Furst, D.E.5
Mayes, M.D.6
-
40
-
-
76649115304
-
A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity
-
Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, et al. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol. 2010;130:694-705.
-
(2010)
J Invest Dermatol
, vol.130
, pp. 694-705
-
-
Sargent, J.L.1
Milano, A.2
Bhattacharyya, S.3
Varga, J.4
Connolly, M.K.5
Chang, H.Y.6
-
41
-
-
84922224910
-
Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms
-
Mahoney JM, Taroni J, Martyanov V, Wood TA, Greene CS, Pioli PA, et al. Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput Biol. 2015;11(1):e1004005.
-
(2015)
PLoS Comput Biol
, vol.11
, Issue.1
-
-
Mahoney, J.M.1
Taroni, J.2
Martyanov, V.3
Wood, T.A.4
Greene, C.S.5
Pioli, P.A.6
-
42
-
-
84935081357
-
Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts
-
Johnson ME, Mahoney JM, Taroni J, Sargent JL, Marmarelis E, Wu MR, et al. Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts. PLoS One. 2015;10(1):e0114017. doi: 10.1371/journal.pone.0114017 .
-
(2015)
PLoS One
, vol.10
, Issue.1
-
-
Johnson, M.E.1
Mahoney, J.M.2
Taroni, J.3
Sargent, J.L.4
Marmarelis, E.5
Wu, M.R.6
|